• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Metformin linked to reduced weight gain and improved insulin sensitivity in obese pregnant women without diabetes

byDavid ArsaniousandShaidah Deghan, MSc. MD
February 4, 2016
in Chronic Disease, Endocrinology, Obstetrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In women who had a BMI of more than 35, antenatal administration of metformin significantly reduced maternal weight gain.

2. There was no significant difference in median neonatal birth-weight between the metformin and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: An estimated one-third of pregnant women in the United States are obese. Lifestyle-intervention studies have not shown improved pregnancy outcomes, and have been generally unsuccessful. Obesity is associated with hyperglycemia and insulin resistance, both of which promote complications such as fetal macrosomia and transient hypoglycemia. Metformin has been shown to increase insulin sensitivity and reduce gestational weight gain in women with gestational diabetes.

Women without diabetes who had a BMI of greater than 35 at 12 to 18 weeks of gestation were randomized to receive metformin or placebo on their first visit after randomization. All the women received advice on healthy eating and exercise. Metformin was initiated at a daily dose of 1.0 g in week 1, and the dose was increased by 0.5 g daily per week to a maximum daily dose of 3.0g. The primary outcome was neonatal birth-weight. None of the fetal/neonatal secondary outcomes demonstrated a significant between-group difference. Maternal weight gain was significantly less in the metformin group compared to placebo. Furthermore, the proportion of women that developed preeclampsia was significantly less in the metformin group compared to placebo. This study draws strength from its racially heterogeneous sample population and their high rate of adherence to the study regimen, but it is limited by underpowering in the secondary outcomes, due to an insufficient recruitment of patients in the study.

Click to read the study, published today in NEJM

Relevant Reading: Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case–control study

RELATED REPORTS

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

In-Depth [randomized controlled trial]: Fetal/neonatal outcomes that were not found to show a significant between-group difference were percentage of: miscarriage (p = 0.12), stillborn (p=0.62), neonatal death (p = 0.49), live birth (p = 0.12), delivered at <37 weeks gestation (p=0.12), median birth weight percentile (p = 0.66), large for gestational age (p=0.79), birth trauma (p=1.00), Apgar score <7 at 5 min (p=0.36), NICU admission (p=0.47), hypoglycemia (p=0.58), hyperbilirubinemia (p=0.36), respiratory distress syndrome (p=0.33). Two of the maternal outcomes demonstrated a significant difference: median maternal weight gain (metformin, 4.6kg vs. placebo 6.3kg; p<0.001) and proportion that developed preeclampsia (metformin, 3% vs. placebo 11.3%; p=0.001).

There was no significant difference between the metformin group and the placebo group in the median neonatal birth-weight z score (p=0.66). Maternal outcomes that were not found to show a significant between-group difference were percentage of: gestational diabetes mellitus (p=0.74), pregnancy-induced hypertension (p=0.93), delivery by caesarian section (p=0.79), and postpartum hemorrhage (p=0.67).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesmetformin
Previous Post

Past marijuana exposure linked to impaired verbal memory

Next Post

Proton radiotherapy for pediatric medulloblastoma demonstrates acceptable toxicity in phase 2 study

RelatedReports

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
StudyGraphics

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

August 10, 2022
#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes
StudyGraphics

#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes

August 9, 2022
Chronic Disease

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

August 2, 2022
#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer
StudyGraphics

#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer

July 26, 2022
Next Post
Proton radiotherapy for pediatric medulloblastoma demonstrates acceptable toxicity in phase 2 study

Proton radiotherapy for pediatric medulloblastoma demonstrates acceptable toxicity in phase 2 study

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

Prophylactic tranexamic acid for decreased hysterectomy blood loss

Prophylactic tranexamic acid for decreased hysterectomy blood loss

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
  • Ovarian cancer screening does not reduce mortality [Classics Series]
  • #VisualAbstract: Sensorimotor retraining improves pain intensity in patients with chronic lower back pain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.